Axsome Therapeutics, Inc. (AXSM)

In Q1 2025, Axsome reported strong revenue growth and exceeded EPS expectations. In May 2025, Axsome presented data from multiple CNS disorder therapies at the American Society of Clinical Psychopharmacology Annual Meeting. In September 2025, CEO Herriot Tabuteau and COO Mark L. Jacobson sold shares of the company's stock. In October 2025, B. Riley initiated coverage with a "buy" rating, and other firms updated their ratings. Axsome is scheduled to release its Q3 2025 financial results on November 3, 2025, with analysts anticipating a year-over-year increase in revenue. As of October 2025, Axsome Therapeutics' stock has risen by 21.30% over the last six months.

No specific information regarding demand seasonality for Axsome Therapeutics' products and services was found. Significant seasonal fluctuations in demand are generally less common for treatments of chronic central nervous system disorders.

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Its commercial product portfolio includes Auvelity for major depressive disorder (MDD), Sunosi for excessive daytime sleepiness, and Symbravo for acute migraine. The company also has a pipeline of investigational medicines, including AXS-05 for Alzheimer's disease agitation and smoking cessation, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia.

Axsome Therapeutics is headquartered in New York, New York, United States. The company's operations extend beyond the U.S., with a geographic footprint that includes Australia, Ireland, Malta, and Canada.

Axsome Therapeutics has engaged in mental health awareness initiatives, partnering with Mental Health America in May 2024 and recognizing Mental Illness Awareness Week in October 2025. In October 2025, Halper Sadeh LLC announced an investigation into whether certain officers and directors of Axsome Therapeutics breached their fiduciary duties to shareholders.

Axsome Therapeutics' ownership includes institutional, individual, and retail investors. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and others, holding a significant portion of the company's shares. CEO Herriot Tabuteau is a significant individual shareholder, and Antecip Capital LLC is also noted as a major shareholder. Insiders collectively own about 22.40% of the company's stock.